
|
Welcome to Genetic Helpdesk ®, an innovative web portal and genetic resource for physicians and healthcare providers.
"Stunning scientific advances in genetics will have little meaning if they do not benefit people."
AE Guttmacher, MD 2002 AJMG
|
|
|
|
Do you need to know if a condition is inherited or how it is inherited?
Do you need to know if there is a genetic test for the condition?
Do you need to know where to send a sample for genetic testing?
Do you need some help with informed consent documentation?
|
| |
Genetic Helpdesk ® has been established to provide healthcare professionals with accurate and current information pertaining to genetics and healthcare.
Ferre Institute's genetic counselors and genetic consultants are available to all healthcare providers by calling us or using our specially designed contact form. We are glad to find a reference, suggest a test, assist in risk assessment or answer a simple question.
Information for this site is provided by the staff of Genetic Helpdesk ®; |
Murray L. Nusbaum, MD
Medical Director
Ferre Genetics |
Luba Djurdjinovic, MS
Genetic Counselor
Ferre Genetics |
Erin E. Houghton, MS, CGC
Genetic Counselor
Ferre Genetics |
|
Ask Us a Question
This unique effort is supported through private donations. |
| Periodically we will use this space to review current abstracts and journal articles of interest. Please contact us if you are looking for a specific article and we will assist you in locating the information. |
| View other journal abstracts here. |
| |
| |
Pregnancy Loss Rates After Midtrimester Amniocentesis
Keith A. Eddleman, MD, et al,
(Obstet Gynecol 2006;108:1067-72)
|
OBJECTIVE: The purpose of this study was to quantify the contemporary procedure-related loss rate after midtrimester amniocentesis using a database generated from patients who were recruited to the First And Second Trimester Evaluation of Risk for Aneuploidy trial.
METHODS: A total of 35,003 unselected patients from the general population with viable singleton pregnancies were enrolled in the First And Second Trimester Evaluation of Risk for Aneuploidy trial between 10 3/7 and 13 6/7 weeks gestation and followed up prospectively for complete pregnancy outcome information. Patients who either did ( study group, n=3,096) or did not (control group, n=31,907) undergo midtrimester amniocentesis were identified from the database. The rate of fetal loss less than 24 weeks of gestation was compared between the two groups, and multiple logisitic regression analysis was used to adjust for potential confounders.
RESULTS: The spontaneous fetal loss rate less than 24 weeks of gestation in the study group was 1.0% and was not statistically different from the background 0.94% rate seen in the control group (P=.74, 95% confidence interval-0.26%, 0.94%). Women undergoing amniocentesis were 1.1 times more likely to have a spontaneous loss (95% confidence interval 0.7-1.5).
CONCLUSION: The procedure-related fetal loss rate after midtrimester amniocentesis performed on patients in a contemporary prospective clinical trial was 0.06%. There was no significant difference in loss rates between those undergoing amniocentesis and those not undergoing anmiocentesis.
|
|
|
|
|
|
|
|
, 2008 Ferre Institute Inc. All rights reserved. Use of this site constitutes acceptance of Ferre Insitute's privacy policy.
The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
|